MediciNova, Inc (MNOV)

Etorro trading 970x250

About MediciNova, Inc

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has a collaboration agreement with BioComo and Mie University for joint development of a SARS-CoV-2 vaccine. MediciNova, Inc. was founded in 2000 and is headquartered in La Jolla, California. Address: 4275 Executive Square, La Jolla, CA, United States, 92037

MediciNova, Inc News and around…

Latest news about MediciNova, Inc (MNOV) common stock and company :

MediciNova to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
03 Sep, 2021 FinancialContent
MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting® 2021, the Annual Meeting of the American Association for the
01 Sep, 2021 FinancialContent
MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
01 Sep, 2021 Yahoo! Finance

LA JOLLA, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an abstract entitled “Improvement of Intracellular Lipid Metabolism by Tipelukast in the Pathogenesis of NASH/NAFLD" has been selected for poster presentation at The Liver Meeting® 2021, the annual meeting of the American Association for the Study of Liver Diseases

MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND
30 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

MediciNova (NASDAQ:MNOV) investors are sitting on a loss of 61% if they invested three years ago
16 Aug, 2021 Yahoo! Finance

If you love investing in stocks you're bound to buy some losers. But the last three years have been particularly tough...

MNOV: Animal Trials Commence Testing MN-166 as an MCM…
16 Aug, 2021 Yahoo! Finance

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Preclinical Studies for BARDA Contract Underway In June 2021, MediciNova, Inc. (NASDAQ:MNOV) announced it initiated a sheep study and also reached an agreement to conduct a mouse study as part of its partnership with the Biomedical Advanced Research and Development Authority (BARDA). The partnership is set up to

Stocks That Hit 52-Week Lows On Friday
13 Aug, 2021 FinancialContent

Friday morning, 94 companies reached new 52-week lows. Significant Points: Wix.com (NASDAQ:WIX) is the ...

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
13 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

MediciNova Reports Second Quarter 2021 Financial Results and Business Update
12 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
11 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

12 Health Care Stocks Moving In Monday's Pre-Market Session
02 Aug, 2021 FinancialContent

Gainers Exicure (NASDAQ:XCUR) stock moved upwards by 35.55% to $1.83 during Monday's pre-market session. The ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
20 Jul, 2021 FinancialContent

Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) stock moved upwards by 36.87% to $3.86 during Tuesday's pre-market ...

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
16 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Analysts Expect 10% Upside For VHT
15 Jul, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Health Care ETF (VHT), we found that the implied analyst target price for the ETF based upon its underlying holdings is $274.05 per unit.

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
09 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

28 Stocks Moving in Tuesday's Pre-Market Session
06 Jul, 2021 FinancialContent

Gainers Odonate Therapeutics, Inc. (NASDAQ: ODT) shares rose 38.3% to $4.80 in pre-market trading following 13G from Ikarian ...

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Ophthalmic Disease
06 Jul, 2021 FinancialContent
MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference
29 Jun, 2021 FinancialContent
MediciNova To Test Ibudilast In BARDA's Validated Mouse Model Of Chlorine-Induced Pulmonary Injury
28 Jun, 2021 FinancialContent

MediciNova Inc(NASDAQ: MNOV)will conduct a mouse studyto investigate the efficacy of MN-166 (ibudilast) in a murine ...

MediciNova to Conduct Mouse Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
28 Jun, 2021 FinancialContent
3 Top Biotech Stocks to Buy Right Now
26 Jun, 2021 FinancialContent

These three biotech stocks recently had positive news coming out of phase 2 trials, making them good choices for growth-oriented investors.

Top 10 Biotech Penny Stocks to Watch in July 2021
22 Jun, 2021 FinancialContent
MediciNov Sees Volume After Zacks Research Raises Price Target To $28
22 Jun, 2021 FinancialContent

MediciNov Inc(NASDAQ: MNOV) sees a trading volume of 18.5 million shares after Zacks Small Cap Research increased the stock ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
22 Jun, 2021 FinancialContent

Gainers Anavex Life Sciences (NASDAQ:AVXL) stock increased by 17.07% to $25.92 during Tuesday's regular session. As ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
22 Jun, 2021 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We're taking a look at the biggest pre-market stock movers for Tuesday as the perfect way to start the day. The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn’t matter if you have $500 in savings or $5 million. Do this now. Top Stock Picker Reveals His Next Potential 500% Winner

21 Stocks Moving in Tuesday's Pre-Market Session
22 Jun, 2021 FinancialContent

Gainers Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) rose 29.2% to $3.71 in pre-market trading as traders circulated an article ...

MNOV: Positive Results for MN-166 in Phase 2 AUD Trial…
22 Jun, 2021 Yahoo! Finance

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Positive Results for MN-166 in Phase 2 AUD Trial On June 21, 2021, MediciNova, Inc. (NASDAQ:MNOV) announced that positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) were published in Translational Psychiatry , a Nature publication ( Grodin et al., 2021 ). The trial was a

MediciNova, Inc (MNOV) is a NASDAQ Common Stock listed in , ,

970x250